Seeking Alpha

Raptor Buy rating reiterated at FBR

  • "Procysbi should become an important alternative for treating patients with nephropathic cystinosis," writes analyst William Tanner reiterating his Outperform and $17 price target. "The pace of market uptake has somewhat debunked the notion that the cost of therapy would adversely position the drug vs. Cystagon."
  • Today's "encouraging" data on RP103 for Huntington's Disease, may also include evidence the drug could be "effective for treating a broad range of conditions characterized by mitochondrial disorders and intracellular cystine accumulation."
  • RPTP +13.4%
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: